(REC) Recordati Industria Chimica - Overview
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: MI (Italy) | Market Cap: 10.336m EUR | Total Return: 2.6% in 12m
Avg Turnover: 18.1M
EPS Trend: 87.7%
Qual. Beats: 0
Rev. Trend: 99.8%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Recordati Industria Chimica e Farmaceutica S.p.A. is an Italy-based pharmaceutical company focused on the development and commercialization of treatments across two primary segments: Specialty/Primary Care and Rare Diseases. The firm maintains a diverse portfolio targeting cardiovascular health, urology, and oncology, while its rare disease division addresses niche metabolic and endocrine disorders. Founded in 1926, the company operates a vertically integrated model that spans research and development through international distribution across Europe, North America, and North Africa.
The pharmaceutical sector is characterized by high barriers to entry due to stringent regulatory requirements and the significant capital investment necessary for clinical trials. Recordati’s business model balances high-volume primary care products with high-margin orphan drugs, which often benefit from extended patent protection and limited competition. Investors can further analyze these fundamental drivers and valuation metrics on ValueRay. This strategic mix allows the company to mitigate risks associated with patent expirations in its legacy portfolio while pursuing growth in specialized medical fields.
- Rare disease segment growth offsets primary care patent expirations and pricing pressure
- Strategic acquisitions of orphan drugs expand international margins and revenue pipelines
- Regulatory approvals for Cushing’s syndrome treatments drive long-term specialty segment valuation
- Foreign exchange volatility in Turkish and Russian markets impacts consolidated earnings results
- Pipeline advancement of Phase II oncology and metabolic assets influences investor sentiment
| Net Income: 471.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 13.43 > 1.0 |
| NWC/Revenue: 13.58% < 20% (prev 24.02%; Δ -10.45% < -1%) |
| CFO/TA 0.10 > 3% & CFO 535.0m > Net Income 471.6m |
| Net Debt (-372.9m) to EBITDA (962.2m): -0.39 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (203.4m) vs 12m ago -1.25% < -2% |
| Gross Margin: 69.38% > 18% (prev 0.68%; Δ 6.87k% > 0.5%) |
| Asset Turnover: 50.51% > 50% (prev 46.72%; Δ 3.79% > 0%) |
| Interest Coverage Ratio: 7.79 > 6 (EBITDA TTM 962.2m / Interest Expense TTM 96.9m) |
| A: 0.07 (Total Current Assets 1.73b - Total Current Liabilities 1.37b) / Total Assets 5.33b |
| B: 0.49 (Retained Earnings 2.62b / Total Assets 5.33b) |
| C: 0.14 (EBIT TTM 754.2m / Avg Total Assets 5.25b) |
| D: 0.80 (Book Value of Equity 2.62b / Total Liabilities 3.27b) |
| Altman-Z'' = 3.85 = AA |
| DSRI: 0.99 (Receivables 659.1m/603.6m, Revenue 2.65b/2.41b) |
| GMI: 0.98 (GM 69.38% / 68.09%) |
| AQI: 0.96 (AQ_t 0.63 / AQ_t-1 0.66) |
| SGI: 1.10 (Revenue 2.65b / 2.41b) |
| TATA: -0.01 (NI 471.6m - CFO 535.0m) / TA 5.33b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at EUR 51.70 with a total of 360,149 shares traded.
Over the past week, the price has changed by +1.00%,
over one month by +3.93%,
over three months by +9.28% and
over the past year by +2.57%.
Recordati Industria Chimica has no consensus analysts rating.
P/E Trailing = 22.4779
P/E Forward = 13.8313
P/S = 3.9513
P/B = 5.2991
P/EG = 1.7719
Revenue TTM = 2.65b EUR
EBIT TTM = 754.2m EUR
EBITDA TTM = 962.2m EUR
Long Term Debt = unknown (none)
Short Term Debt = 16.6m EUR (from shortLongTermDebt, last quarter)
Debt = 7.60m EUR (Leases only: 7.60m)
Net Debt = -372.9m EUR (calculated: Debt 7.60m - CCE 380.5m)
Enterprise Value = 9.96b EUR (10.3b + Debt 7.60m - CCE 380.5m)
Interest Coverage Ratio = 7.79 (Ebit TTM 754.2m / Interest Expense TTM 96.9m)
EV/FCF = 22.60x (Enterprise Value 9.96b / FCF TTM 440.8m)
FCF Yield = 4.42% (FCF TTM 440.8m / Enterprise Value 9.96b)
FCF Margin = 16.62% (FCF TTM 440.8m / Revenue TTM 2.65b)
Net Margin = 17.79% (Net Income TTM 471.6m / Revenue TTM 2.65b)
Gross Margin = 69.38% ((Revenue TTM 2.65b - Cost of Revenue TTM 812.1m) / Revenue TTM)
Gross Margin QoQ = 71.60% (prev 71.37%)
Tobins Q-Ratio = 1.87 (Enterprise Value 9.96b / Total Assets 5.33b)
Interest Expense / Debt = 1.27k% (Interest Expense 96.9m / Debt 7.60m)
Taxrate = 23.76% (47.7m / 200.8m)
NOPAT = 575.0m (EBIT 754.2m * (1 - 23.76%))
Current Ratio = 1.26 (Total Current Assets 1.73b / Total Current Liabilities 1.37b)
Debt / Equity = 0.00 (Debt 7.60m / totalStockholderEquity, last quarter 2.06b)
Debt / EBITDA = -0.39 (Net Debt -372.9m / EBITDA 962.2m)
Debt / FCF = -0.85 (Net Debt -372.9m / FCF TTM 440.8m)
Total Stockholder Equity = 1.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.98% (Net Income 471.6m / Total Assets 5.33b)
RoE = 24.25% (Net Income TTM 471.6m / Total Stockholder Equity 1.94b)
RoCE = 19.02% (EBIT 754.2m / Capital Employed (Total Assets 5.33b - Current Liab 1.37b))
RoIC = 14.89% (NOPAT 575.0m / Invested Capital 3.86b)
WACC = 6.89% (E(10.3b)/V(10.3b) * Re(6.90%) + (debt cost/tax rate unavailable))
Discount Rate = 6.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 50.13 | Cagr: 0.64%
[DCF] Terminal Value 75.44% ; FCFF base≈440.8m ; Y1≈442.6m ; Y5≈468.9m
[DCF] Fair Price = 37.68 (EV 7.29b - Net Debt -372.9m = Equity 7.67b / Shares 203.5m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 87.67 | EPS CAGR: 13.72% | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.79 | Revenue CAGR: 11.53% | SUE: 1.10 | # QB: 1
EPS current Year (2026-12-31): EPS=2.49 | Chg30d=+0.23% | Revisions=-50% | GrowthEPS=+17.5% | GrowthRev=+6.2%
EPS next Year (2027-12-31): EPS=3.71 | Chg30d=+0.46% | Revisions=+14% | GrowthEPS=+15.8% | GrowthRev=+8.2%
[Analyst] Revisions Ratio: -50%